RAC media coverage, page-1391

Well your correct in saying wild speculation on the SP but I guess we will never know we did get to $4.20 with little marketing so is $8 really wild speculation who knows.
Specially when there has been evaluation put out that is higher than $8 for RAC.

I understand very well why under the radar approach was said.
And too an extent I agree as it might of been in best interests at the time for RAC.
But As an investor you want the world to know about your stock,
any stock that's what drives the SP.
and maybe we would be in a better position than we are now with the SP.

I'm holding till we get bought out so the SP means very little but I still don't want to see it down no holder does.
we all have our own opinions and I just think that bit could of been played differently.
That's all,
that's my only thing I wish was done differently.
overall that's about it.
Might end up being the best strategy who knows.
Also with AML I'm sure DCB can use the historical data specifically since it's recognised by the FDA.
We have so much news to come out by end of June ontop of that who knows what news will come out of this months trip.
I also spoke to DCB and he did say a partnership could come any day if they like what they see.
And although we still have results coming to show to validate data,
We still have some compelling data to show potential partners